Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer has published three papers demonstrating its Proteograph Product Suite's ability to uncover novel plasma proteomic insights during spaceflight. Data from the SpaceX Inspiration4 mission revealed acute changes in oxidative stress, brain homeostasis, and coagulation, with many alterations persisting six months post-flight. Seer’s technology allows comprehensive profiling of astronauts' physiological responses, aiding precision medicine and biomarker discovery. The studies include a substantial dataset from multiple space missions and highlight the Proteograph XT Assay Kit’s capabilities in detecting over 60,000 peptides and 8,000 proteins in plasma samples.
Seer has announced the completion of a groundbreaking mass spectrometry study by PrognomiQ, utilizing Seer's Proteograph Product Suite and the Thermo Scientific Orbitrap Astral mass spectrometer. This multi-cancer case-control study involved 2,840 subjects and identified over 13,000 protein groups, with an average of 8,200 protein groups per sample. The study, conducted across 77 clinical sites in the U.S., showcases the combined power of Seer and Thermo Fisher's technologies in early cancer detection. The findings will be presented at the ASMS Conference on June 6.
Seer, Inc. (Nasdaq: SEER), a life sciences company, reported Q1 2024 financial results. Achieved $3.1M in revenue, expanded STAC program to Europe, validated Proteograph Product Suite, launched Insights Grant Program, authorized $25M share repurchase program. Experienced a 24% revenue decrease primarily from product and related party revenue. Operating expenses decreased by 10%. Net loss was $20.7M. Cash position at $359.2M. Board authorized $25M share repurchase program. Full year revenue guidance for 2024 is $16-18M.
Seer, Inc. (Nasdaq: SEER) has launched a new Seer Technology Access Center in Bonn, Germany, to provide European life sciences researchers with access to the Seer Proteograph™ Product Suite and mass spectrometry technologies. The facility aims to support unbiased proteomic studies, accelerate biomarker discovery, and drug development. The European STAC will offer programs to enhance the availability of state-of-the-art proteomics technologies and assist researchers in expanding their research scope.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.